Status epilepticus is treated in a rapid, time-sensitive sequence: fast-acting sedatives first, followed by longer-lasting anti-seizure medications, and then anesthetic agents if seizures persist. The American Epilepsy Society breaks this into three treatment phases that unfold over roughly 40 minutes, with each escalation carrying more risk and requiring more intensive monitoring.
Why Timing Matters
A seizure that lasts beyond five minutes is unlikely to stop on its own and is classified as status epilepticus. The longer it continues, the harder it becomes to treat. Each phase of therapy tends to be less effective than the one before it, which is why guidelines emphasize aggressive early treatment. The 30-day mortality rate for status epilepticus overall is about 8.5%, but that figure rises sharply with age: adults older than 65 face roughly six and a half times the mortality risk compared to adolescents. Other factors that worsen outcomes include an acute underlying cause (like a stroke or brain infection), the absence of a prior epilepsy diagnosis, and the need for prolonged anesthetic treatment.
Stabilization: The First Five Minutes
Before any medication is given, the focus is on keeping the person safe and assessing basic functions: airway, breathing, circulation, blood sugar. This is the window where bystanders or first responders position the person on their side, clear the area, and call for emergency help. No anti-seizure drugs are administered yet. Medical teams use this time to establish IV access, check glucose levels, and prepare for the next phase.
First-Line Treatment: 5 to 20 Minutes
Benzodiazepines are the standard first treatment once a seizure has lasted five minutes. These drugs work quickly by calming overactive electrical signaling in the brain. The specific drug depends on the situation and what’s available:
- Midazolam can be given as an injection into the muscle or sprayed into the nose, making it the go-to option when there’s no IV line. It’s often the fastest option in the field.
- Lorazepam is preferred when IV access is available because it reaches the brain quickly and its effects last longer than some alternatives.
- Diazepam is another IV option, and it can also be given rectally, which makes it useful for home or school emergency plans.
A second dose of the same benzodiazepine can be given if the seizure doesn’t stop within 5 to 10 minutes of the first dose. This first-line phase has the highest success rate of any step in the process.
Second-Line Treatment: 20 to 40 Minutes
If benzodiazepines fail, the seizure has now been going for at least 20 minutes and the treatment shifts to longer-acting anti-seizure medications given intravenously. Three options are considered equally reasonable: fosphenytoin, valproic acid, and levetiracetam. These drugs work through different mechanisms than benzodiazepines and take longer to administer, often requiring a slow IV infusion over 10 to 20 minutes.
Phenobarbital is a backup option if none of those three are available, though it carries a higher risk of side effects like drops in blood pressure and breathing suppression. Evidence shows that second-line therapy is already less effective than the initial benzodiazepine, which reinforces why the first phase needs to happen quickly and decisively.
Third-Line Treatment: Beyond 40 Minutes
When seizures continue past 40 minutes despite two rounds of medication, the situation is now considered refractory status epilepticus. At this point, there is no strong evidence favoring one approach over another. Options include repeating a second-line medication or escalating to anesthetic doses of drugs like propofol, midazolam, or pentobarbital. These are given at doses high enough to induce a medically controlled coma, and the patient requires a breathing tube, intensive care admission, and continuous brain wave (EEG) monitoring.
The goal of the medically induced coma is to completely suppress the abnormal electrical activity in the brain. Once seizure activity has been quiet for 24 to 48 hours, doctors gradually reduce the anesthetic to see whether seizures return. If they do, the process restarts.
Super-Refractory Status Epilepticus
When seizures persist or return after 24 hours of anesthetic treatment, the condition is classified as super-refractory. This is the most dangerous and difficult stage. Treatment options become less conventional and more experimental.
One approach that has shown promise is the ketogenic diet, a very high-fat, very low-carbohydrate feeding plan (roughly 90% fat) delivered through a feeding tube. In small studies, about 79% to 87% of patients with super-refractory status epilepticus responded to the diet, though results typically took a median of about six and a half days to appear. The diet works by shifting the brain’s energy source from glucose to compounds called ketone bodies, which appear to have seizure-suppressing effects.
Other options at this stage include surgical removal of the brain tissue generating seizures (when a clear source can be identified), vagus nerve stimulation, deep brain stimulation, and electroconvulsive therapy. None of these have large-scale trial data behind them, and decisions are made case by case.
Non-Convulsive Status Epilepticus
Not all status epilepticus involves visible shaking. Non-convulsive status epilepticus causes prolonged seizure activity in the brain without obvious physical convulsions. The main symptom is altered mental status: confusion, unresponsiveness, or a prolonged “post-seizure” state that doesn’t improve. Some patients show subtle signs like repetitive lip movements, unusual eye movements, or small twitches in the face or hands.
This form is widely underdiagnosed because it mimics other causes of confusion, from strokes to metabolic problems. Definitive diagnosis requires an EEG, but emergency physicians are encouraged to suspect it in anyone with unexplained altered mental status, especially after a known seizure or in the setting of acute brain injury. Treatment follows the same stepwise approach as convulsive status epilepticus: benzodiazepines first, then longer-acting anti-seizure medications.
Treatment in Children
The same general sequence applies to children, but all drug doses are calculated by body weight. Children receive lorazepam at the same weight-based dose as adults (0.1 mg/kg IV, up to 4 mg). If there’s no IV access, intranasal or buccal midazolam at 0.3 mg/kg is the standard alternative. For second-line treatment, levetiracetam, fosphenytoin, and valproic acid are all options, with doses adjusted for the child’s weight. Infants under one month old are a special case: phenobarbital is often the preferred second-line drug because some of the other options are less well studied in newborns.
Children have a significantly lower 30-day mortality rate from status epilepticus (about 1.8%) compared to adults (10.2%), likely because the underlying causes in children are more often treatable, such as febrile seizures or infections, rather than strokes or advanced brain disease.
What Predicts a Worse Outcome
Four factors consistently predict higher mortality at both 30 days and one year: older age, no prior history of epilepsy, an acute underlying cause (like a new stroke, brain tumor, or serious infection), and failure to respond to initial treatments. Interestingly, people who already have epilepsy tend to do better when they develop status epilepticus, possibly because their seizures are more likely to respond to standard medications. Prolonged use of anesthetic-level drugs (three or more days) is also associated with higher mortality, though this likely reflects the severity of the underlying condition rather than a direct effect of the drugs themselves.